Image

Gastric POCUS for Airway Management in Patients Using Glucagon-like Peptide-1 Receptor Agonist (Multicentric)

Gastric POCUS for Airway Management in Patients Using Glucagon-like Peptide-1 Receptor Agonist (Multicentric)

Recruiting
18-90 years
All
Phase N/A

Powered by AI

Overview

1\. Introduction

Scheduled surgery requires patients to undergo a preoperative fasting period of at least 6 hours to reduce the risk of perioperative pulmonary aspiration. However, certain medications and conditions may delay gastric emptying, potentially increasing aspiration risk. These include diabetic gastroparesis and the use of glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of diabetes and obesity.

GLP-1 receptor agonists are widely used due to their beneficial effects on glycemic control and weight reduction. However, one of their known effects is delayed gastric emptying, which may result in increased residual gastric content despite adherence to standard fasting guidelines. Recent reports have described cases of pulmonary aspiration during anesthesia in patients receiving GLP-1 receptor agonists, even after appropriate fasting.

Given the increasing use of these medications, there is a need for objective assessment tools to evaluate gastric content in the perioperative setting. Gastric ultrasonography has emerged as a non-invasive bedside technique that may help identify patients at increased risk of aspiration and guide airway management strategies.

Description

2\. Hypothesis

Gastric ultrasonography performed by trained anesthesiologists is a useful tool for assessing gastric content and may support clinical decision-making in airway management in patients treated with GLP-1 receptor agonists.

3\. Methodology

This is a prospective, observational cohort study conducted at participating centers.

The study population consists of adult patients undergoing scheduled surgery under general anesthesia following a standard preoperative fasting period.

Inclusion criteria:

  • Patients receiving treatment with GLP-1 receptor agonists
  • Age ≥18 years
  • Scheduled surgery after a fasting period between 6 and 8 hours
  • ASA physical status I-III
  • Ability to provide informed consent

Exclusion criteria:

  • History of esophagogastric pathology or prior upper abdominal surgery
  • Hiatal hernia or gastroesophageal reflux disease
  • Autonomic nervous system disorders
  • Neurological or neuromuscular diseases
  • Use of medications affecting gastric emptying (e.g., opioids or prokinetics)
  • Pregnancy
  • Presence of clinically significant arrhythmias

4\. Description of the Intervention

Immediately prior to anesthesia induction, gastric ultrasonography will be performed by trained investigators at participating centers, with the patient in both supine and right lateral decubitus positions.

Qualitative, semi-quantitative, and quantitative assessments of gastric content and volume will be performed according to the methodology described by Perlas et al. Data will be recorded in a standardized study database.

Anesthetic and surgical management will proceed according to routine clinical practice.

5\. Ethical, Legal, and Economic Considerations

Written informed consent will be obtained from all participants prior to study inclusion.

This is an observational study with no modification of standard clinical care. No additional risks beyond routine clinical practice are anticipated.

Gastric ultrasonography will be performed using equipment available at participating centers, and no additional costs are expected.

6\. Results

Study data will be analyzed by the investigators. Results will be disseminated through scientific publications and presentations.

Eligibility

Inclusion Criteria:

Adults patients ,ASA I-III, taking GLP-1 analog medications, undergoing scheduled surgery.

Exclusion Criteria:

  1. \- History of esophagogastric pathology or previous abdominal surgery.
  2. \- Hiatal hernia/gastroesophageal reflux disease.
  3. \- Autonomic nervous system disorders.
  4. \- Neurological or neuromuscular diseases.
  5. \- Use of medications/drugs that affect autonomic regulation and delay gastric emptying (opioids) or potentiate it (prokinetics).
  6. \- Pregnancy.
  7. \- Presence of arrhythmias.

Study details
    Aspiration Pneumonia

NCT06666049

Clinica Universidad de Navarra, Universidad de Navarra

14 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.